Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03328520 · ClinicalTrials.gov registry record · NA
WILD 5 Wellness, A 30-Day Intervention
A NA study of Depression and Anxiety, sponsored by Beloit College.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT03328520: Completed NA study of Depression and Anxiety, sponsored by Beloit College.
NCT03328520 is a NA study of Depression and Anxiety that has completed, run by Beloit College. The registered enrollment target is 33 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03328520, a NA study of Depression and Anxiety, has completed, sponsored by Beloit College.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to explore the efficacy and feasibility of an integrated, prescriptive, and trackable wellness intervention combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition in First Year Beloit College students self-selected into a wellness focused first year initiative. This program is called "WILD 5 Wellness: A 30-Day Intervention".
Primary Outcome
PHQ-9 is a self reported depression scale. It is a 9-item scale with scores ranging from 0-27. Lower scores denote improvement.
Conditions Studied
Interventions
- BEHAVIORAL WILD 5 Wellness Intervention
Study Locations (1)
Wisconsin
- Beloit College - Beloit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2017-10-24 |
| Est. Completion | 2017-11-29 |
| Phase | NA |
What the finished NCT03328520 record still lists
NCT03328520 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (96% lower).
The record links to 4 conditions, with Depression appearing as the primary indexed condition, and to 1 intervention - of which WILD 5 Wellness Intervention is the first listed.
NCT03328520 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT03328520 about?
NCT03328520 is a clinical study titled "WILD 5 Wellness, A 30-Day Intervention". The purpose of this study is to explore the efficacy and feasibility of an integrated, prescriptive, and trackable wellness intervention combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition in First Year Beloit College students self-selected in...
What is the current status of trial NCT03328520?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2017-10-24. Estimated completion is 2017-11-29.
What conditions does trial NCT03328520 study?
This clinical trial studies the following conditions: Depression, Anxiety, Wellness, Cognitive Functioning.
What interventions are being tested in trial NCT03328520?
The interventions under investigation include: WILD 5 Wellness Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT03328520?
This trial is sponsored by Beloit College, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03328520 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03328520's enrollment target sits among peer trials
33 549th of 679 higher than 127 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reaching Out to Distressed Medical Residents, Fellows and Faculty
RECRUITING · NA
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
Cold and Heat Investigation to Lower Levels of Depression
RECRUITING · NA
-
Dosing rTMS for Depression Post-SCI
RECRUITING · NA
-
Exploring Virtual Reality Adventure Training Exergaming
RECRUITING · NA
-
Brief Interventions for Coping with Distress
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy